APIC – Active Pharmaceutical Ingredients Committee

APIC represents producers of APIs and API intermediates in Europe.


Its membership consists of 60 companies, located all over Europe, and of 4 national industry associations.


For around 2/3 of its members, selling APIs and intermediates is their major business while ca. 1/3 of the members are primarily marketing final medicinal products. APIC’s focus is on worldwide Quality, Good Manufacturing Practice (GMP) and Regulatory matters relating to APIs and intermediates.


N. Fennelly (Pharmachemical Ireland)


Active pharmaceutical ingredients


AbbVie (NL), Ajinomoto-Omnichem SA/NV (BE), Albemarle Europe sprl (BE), Ashland Specialties (UK), Aspen Oss B.V. (NL), Bachem SA (CH), BASF (SE) (DE) (Orgamol – Ciba), BASF Pronova BioPharma, Boehringer Ingelheim Pharma KG (DE), Bracco Suisse SA (CH), Cambrex Karlskoga AB (SE), Carbogen Amcis (CH), Cargill NV (BE) (IT), Celgene Chemicals GmbH (CH), Colgate Palmolive Europe Sarl (CH), Croda Europe Ltd (UK), CU Chemie Uetikon GmbH (DE), Dipharma Francis Srl (IT), Dow Corning Europe AS (FR), DPx Fine Chemicals (AU), DSM Sinochem Pharmaceuticals (NL),DSM Nutritional Products (CH), EGIS Pharmaceuticals (HU), ESCO-European Salt Company (DE), Evonik (DE, FR), F.I.S. SpA (IT), Genzyme Ltd.(Sanofi) (UK), Hovione FarmaCiencia SA (PT), Janssen Pharmaceutica (J&J. Cilag)(BE), Lesaffre (FR), Jungbunzlauer Ladenburg GmbH (DE), Lonza AG (CH), Macfarlan Smith Ltd (UK), Medichem SA (ES), Merck KGaA (DE), Novacyl (FR), Novo Nordisk A/S (FEF Chemicals) (DK), Ofichem BV (NL), Orion Corporation, Fermion Oy (FI), PCAS Pharma Synthesis (FR) (DE), Pfizer Inc. (BE), Piramal Healthcare UK Ltd (UK), PolyPeptide Laboratories AB (SE), Roquette Frères SA (FR), Sandoz (Novartis, Hexal) (DE), Sanofi (FR), Seratec (FR), Siegfried Ltd (CH), Sifavitor/ Infagroup (IT), Swords Labs Ltd (BristolMyers) (IE), Tereos (FR), Teva Pharmaceuticals Ind. Ltd (IL) (IT) (HU), Uquifa SA (ES), Xellia Pharmaceuticals ApS (DK) (NO), Zentiva k.s.(Sanofi) (CZ)


4 National Federations:
AFAQUIM (ES), Aschimfarma (Federchimica) (IT), BioPharmaChem Ireland (IBEC) (IE), SICOS (FR)


Networking/ Advocacy: to continually improve our contacts and to increase the profile of APIC with all relevant stakeholders.
Level Playing Field: to strongly advocate regulatory compliance in all global markets and its enforcement through inspection.
Post approval change authorisation: to put the responsibility to manage change into the hands of industry.
Harmonisation: to support global harmonisation in the fields of quality and regulatory affairs.


For more information:


Sector Group Manager

Pieter van der Hoeven


Annick Bonneure